61st European Renal Association Congress (ERA 2024)

Stockholm, Sweden 23 May 2024 - 26 May 2024

Kidney, heart benefits FLOW with semaglutide

10 Jul 2024 by

Semaglutide reduces the risk of major kidney disease-related events and death from cardiovascular causes in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), as shown in the FLOW* study presented at ERA 2024.

Kidney, heart benefits FLOW with semaglutide

10 Jul 2024

Dual ACE inhibitor plus ARB therapy worsens kidney status in CKD

11 Jun 2024 by

Use of dual therapy with ACE inhibitors and ARBs tends to elevate the risk of renal outcomes in people with or without chronic kidney disease (CKD), reports a study presented at ERA 2024.

Dual ACE inhibitor plus ARB therapy worsens kidney status in CKD

11 Jun 2024

Oral tacrolimus benefits haemodialysis patients with uraemic pruritus

11 Jun 2024 by

A study from Iran presented at ERA 2024 demonstrated the potential of oral tacrolimus to deliver an antipruritic effect in haemodialysis patients with uraemic pruritus.

Oral tacrolimus benefits haemodialysis patients with uraemic pruritus

11 Jun 2024

Survival, hospitalization outcomes similar between biweekly, thrice-weekly dialysis schedules

10 Jun 2024 by

A twice-weekly haemodialysis schedule does not appear to increase death and hospitalization rates at 2 years compared with a thrice-weekly schedule, although some patients on the biweekly schedule may require medication dose adjustments, as reported in the prospective multicentre nonrandomized TATH* trial.

Survival, hospitalization outcomes similar between biweekly, thrice-weekly dialysis schedules

10 Jun 2024

Iptacopan safe, effective in patients with C3G

10 Jun 2024 by

Use of iptacopan along with supportive care results in significant reductions in proteinuria at 6 months in patients with C3 glomerulopathy (C3G), a rare and severe form of proliferative glomerulonephritis brought about by the dysregulation of alternative complement pathway (AP), as shown in the APPEAR-C3G study. It is also well tolerated and has a favourable safety profile.

Iptacopan safe, effective in patients with C3G

10 Jun 2024

Benefits of investigational IgA nephropathy drug persist for 72 weeks

09 Jun 2024 by

Patients with IgA nephropathy (IgAN) who have been treated with atacicept continue to show improvement in disease status through 72 weeks, with consistent reductions in the key indicators of IgAN and the kidney function remaining stable, according to the open-label extension phase of the phase IIb ORIGIN study.

Benefits of investigational IgA nephropathy drug persist for 72 weeks

09 Jun 2024

Atrasentan a new player in the IgAN treatment field?

07 Jun 2024 by

In the prespecified interim analysis of the phase III ALIGN study, the investigational drug atrasentan shows promising signals when added to standard supportive care with a renin-angiotensin system (RAS) inhibitor in patients with IgA nephropathy (IgAN).

Atrasentan a new player in the IgAN treatment field?

07 Jun 2024